跳至主要内容
临床试验/NCT02141178
NCT02141178撤回不适用

Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?

University of Pittsburgh1 个研究点 分布在 1 个国家开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Pain

研究概览

简要总结

Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.

The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with carpal tunnel syndrome undergoing surgery

排除标准

  • Non english speaking
  • Allergy to bupivacaine or exparel

研究组 & 干预措施

Bupivacaine

Active Comparator

Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery

干预措施: Bupivacaine (Drug)

Exparel

Experimental

Patients will received Exparel subcutaneously for local anesthesia during surgery

干预措施: Exparel (Drug)

结局指标

主要结局

Pain

时间窗: Starting immediately after surgery and then every 8 hours for 10 days

Pain will be evaluated using an 11-point ordinal scale (0-10)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Comparison of Bupivacaine and Exparel for Carpal... | 临床试验